Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Jesús García-Foncillas as Clinical Advisor of Invitrocue.
January 15, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Jesús García-Foncillas as Clinical Advisor of Invitrocue.
Professor Jesús is an experienced oncology researcher with 25 years of experience in cancer diagnosis and treatment. He holds multiple executive leadership positions at “Fundacion Jimenez Diaz” Autonomous University of Madrid, Spain (FJD-UAM). He is the Director of the University Cancer Institute and the Department of Oncology at FJD-UAM, and the Director of Translational Oncology Division at the Health Research Institute FJD-UAM.
Professor Jesús also serves as the Coordinator of the Comprehensive Cancer Program of four University Hospitals located in Madrid. In addition to his research work, Professor Jesús has been the Vice President for the National Medical Oncology Commission, Ministry of Health and Consumer Affairs Council on Medical Specialities for the past eight years. He holds a Doctorate from the School of Medicine, University of Navarra and has authored more than 220 articles and several books on cancer.
Commenting on the appointment, Dr. Steven Fang, Executive Chairman, Invitrocue, said:
“We are very excited to welcome Professor Jesús to our highly committed and respected team of clinical advisors. As a highly-regarded opinion leader in Spain, Professor Jesús will play an important role in facilitating our collaborations with leading hospitals, pharmaceutical companies and local cancer research centres in Spain, working towards accelerating the global roll-out and commercialisation of our proprietary Onco-PDOTM personalised cancer screening test.”
-ENDS-
For more information contact:
Martin D. Bach, VP Operations
T: +65 6460 0497
About Invitrocue
Invitrocue is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. Invitrocue’s Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).
Invitrocue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.
Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com
